Evidence map›Paper›PMID 31170018›Full record

ReviewJournal of global oncology2019

Is Colorectal Cancer Screening Appropriate in Nigeria?

Gregory C Knapp, Olusegun I Alatise, Olalekan O Olasehinde, Ademola Adeyeye, Omobolaji O Ayandipo, Martin R Weiser, T Peter Kingham

Open access · goldAbstract readReview
In one paragraph

Review in Journal of global oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Gregory C KnappMemorial Sloan Kettering Cancer Center, New York, NY.
Olusegun I AlatiseObafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Nigeria.
Olalekan O OlasehindeObafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Nigeria.
Ademola AdeyeyeUniversity of Ilorin Teaching Hospital, Ilorin, Nigeria.
Omobolaji O AyandipoUniversity College Hospital, Ibadan, Nigeria.
Martin R WeiserMemorial Sloan Kettering Cancer Center, New York, NY.
T Peter KinghamMemorial Sloan Kettering Cancer Center, New York, NY.
Memorial Sloan Kettering Cancer Center · USObafemi Awolowo University Teaching Hospitals Complex · NGUniversity College Hospital, Ibadan · NGUniversity of Ilorin Teaching Hospital · NG

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeThe global burden of colorectal cancer (CRC) will continue to increase for the foreseeable future, largely driven by increasing incidence and mortality in low- and middle-income countries (LMICs) such as Nigeria.

methodsWe used the Wilson-Jungner framework (1968) to review the literature relevant to CRC screening in Nigeria and propose areas for future research and investment.

resultsScreening is effective when the condition sought is both important and treatable within the system under evaluation. The incidence of CRC is likely increasing, although the exact burden of disease in Nigeria remains poorly understood and access to definitive diagnosis and treatment has not been systematically quantified. In high-income countries (HICs), CRC screening builds on a well-known natural history. In Nigeria, a higher proportion of CRC seems to demonstrate microsatellite instability, which is dissimilar to the molecular profile in HICs. Prospective trials, tissue banking, and next-generation sequencing should be leveraged to better understand these potential differences and the implications for screening. Fecal immunochemical test for hemoglobin (FIT) is recommended for LMICs that are considering CRC screening. However, FIT has not been validated in Nigeria, and questions about the impact of high ambient temperature, endemic parasitic infection, and feasibility remain unanswered. Prospective trials are needed to validate the efficacy of stool-based screening, and these trials should consider concomitant ova and parasite testing.

conclusionUsing the Wilson-Jungner framework, additional work is needed before organized CRC screening will be effective in Nigeria. These deficits can be addressed without missing the window to mitigate the increasing burden of CRC in the medium to long term.

Indexed as

Colorectal NeoplasmsEarly Detection of CancerFecesHemoglobinsHumansIncidenceNigeriaOccult BloodHemoglobins

Identifiers

PMID31170018
PMCPMC6613663
OpenAlexW2948476720

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.